TY - JOUR
T1 - Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel
T2 - Results of phase 1 and 2 trials
AU - Duvic, M.
AU - Friedman-Kien, A. E.
AU - Looney, D. J.
AU - Miles, S. A.
AU - Myskowski, P. L.
AU - Scadden, D. T.
AU - Von Roenn, J.
AU - Galpin, J. E.
AU - Groopman, J.
AU - Loewen, G.
AU - Stevens, V.
AU - Truglia, J. A.
AU - Yocum, R. C.
PY - 2000
Y1 - 2000
N2 - Objective: To evaluate the efficacy and safety of topical alitretinoin gel (9-cis-retinoic acid [LGD1057], Panretin gel; Ligand Pharmaceuticals, Inc, San Diego, Calif) in cutaneous Kaposi sarcoma (KS). Design: Open-label, within-patient, controlled, dose-escalating phase 1 and 2 clinical trials. In all patients, 1 or more cutaneous KS lesions were treated with alitretinoin gel, and at least 2 other lesions served as untreated controls for up to 16 weeks. Alitretinoin (0.05% or 0.1% gel) was applied twice daily for the first 2 weeks and up to 4 times daily thereafter, if tolerated. Setting: Nine academic Clinical centers. Patients: One hundred fifteen patients with biopsy-proven acquired immunodeficiency syndrome (AIDS)-related KS. Main Outcome Measures: AIDS Clinical Trials Group response criteria. Results: Statistically significant clinical responses were observed in 31 (27%) of 115 patients for the group of treated index lesions compared with 13 (11%) for the group of untreated control lesions (P < .001). Responses occurred with low CD4+ lymphocyte counts (<200 cells/μL) and in some patients with refractory response to previous systemic anti-KS therapy. The incidence of disease progression was significantly lower for treated indexlesions compared with untreated control lesions (39/115 [34%] vs 53/115 [46%]; P=.02). Alitretinoin gel generally was well tolerated, with 90% of treatment-related adverse events confined to the application site and only mild or moderate in severity. Conclusions: Alitretinoin gel has significant antitumor activity as a topical treatment for AIDS-related KS lesions, substantially reduces the incidence of disease progression in treated lesions, and is generally well tolerated.
AB - Objective: To evaluate the efficacy and safety of topical alitretinoin gel (9-cis-retinoic acid [LGD1057], Panretin gel; Ligand Pharmaceuticals, Inc, San Diego, Calif) in cutaneous Kaposi sarcoma (KS). Design: Open-label, within-patient, controlled, dose-escalating phase 1 and 2 clinical trials. In all patients, 1 or more cutaneous KS lesions were treated with alitretinoin gel, and at least 2 other lesions served as untreated controls for up to 16 weeks. Alitretinoin (0.05% or 0.1% gel) was applied twice daily for the first 2 weeks and up to 4 times daily thereafter, if tolerated. Setting: Nine academic Clinical centers. Patients: One hundred fifteen patients with biopsy-proven acquired immunodeficiency syndrome (AIDS)-related KS. Main Outcome Measures: AIDS Clinical Trials Group response criteria. Results: Statistically significant clinical responses were observed in 31 (27%) of 115 patients for the group of treated index lesions compared with 13 (11%) for the group of untreated control lesions (P < .001). Responses occurred with low CD4+ lymphocyte counts (<200 cells/μL) and in some patients with refractory response to previous systemic anti-KS therapy. The incidence of disease progression was significantly lower for treated indexlesions compared with untreated control lesions (39/115 [34%] vs 53/115 [46%]; P=.02). Alitretinoin gel generally was well tolerated, with 90% of treatment-related adverse events confined to the application site and only mild or moderate in severity. Conclusions: Alitretinoin gel has significant antitumor activity as a topical treatment for AIDS-related KS lesions, substantially reduces the incidence of disease progression in treated lesions, and is generally well tolerated.
UR - http://www.scopus.com/inward/record.url?scp=0034528018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034528018&partnerID=8YFLogxK
M3 - Article
C2 - 11115156
AN - SCOPUS:0034528018
SN - 0003-987X
VL - 136
SP - 1461
EP - 1469
JO - Archives of Dermatology
JF - Archives of Dermatology
IS - 12
ER -